Sonia Elena Popovici: Redefining Hemorrhagic Shock Through Cellular and Molecular Insights
Sonia Elena Popovici, Specialist in Anesthesiology and Critical Care Medicine at Timișoara Municipal Emergency Clinical Hospital, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Biomedicines, adding:
”Pleased to share that our narrative review is now published in Biomedicines (MDPI, Q1):
‘Cellular and Molecular Mechanisms of Hemorrhagic Shock: Biological Rationale for Individualized Fluid Resuscitation Strategies and Multimodal Monitoring’
Biomedicines 2026, 14(8), 1678 — open access.
Hemorrhagic shock is still too often managed as a volume problem. In this review we bring the discussion back to what actually happens at the cellular and molecular level — endothelial and glycocalyx injury, the coagulopathy of trauma, the metabolic shift, and the individual genetic variability that shapes how a given patient responds.
From that biology, we argue for a time-based, individualized approach to resuscitation and for multimodal monitoring rather than a one-size-fits-all protocol.
Grateful to work with this team: Dr. medic Petru Bucuras, Dr. Stelian Adrian Ritiu, Prof. Dr. Marius Papurica, Prof. Dr. Dorel Sandesc, Dr. Adelina Baloi, Dr. Daiana Toma, Dr. Norbert Wellmann, Dr. Claudiu Rafael Barsac, and Prof. Dr. Ovidiu Bedreag.”
Title: Cellular and Molecular Mechanisms of Hemorrhagic Shock: Biological Rationale for Individualized Fluid Resuscitation Strategies and Multimodal Monitoring
Authors: Stelian Adrian Ritiu, Sonia Elena Popovici, Marius Papurica, Dorel Sandesc, Adelina Baloi, Daiana Toma, Norbert Wellmann, Petru Bucuras, Claudiu Rafael Barsac, Ovidiu Bedreag
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM
-
Sep 20, 2026, 00:46Julia R. Coleman: Platelet Biology and Sex Differences in the Plasma Milieu at AAST 2026